Kai Rossen received his Diploma in chemistry in Germany, an M.S. (with Maurice Brookhart) from the University of North Carolina, Chapel Hill, and his Ph.D. (with Bruce Ganem) from Cornell. After beginning his career at Bayer, he joined the Process Research Department of Merck & Co. in Rahway where he was involved in the synthesis of several currently marketed drugs and in catalyst development.
Dr. Rossen returned to Germany in 2000 and has worked for the Fine Chemicals Division of Degussa (now Evonik), for Sanofi in Frankfurt and recently as Vice President of Process Chemistry at Lundbeck in Copenhagen, Denmark. In October 2020, Dr. Rossen returned to Sanofi in Frankfurt where he Chief Scientific Officer in the part of Sanofi that is focusing on API production and which is scheduled to be separated. He currently is CSO of EuroAPI, a new company created from Sanofi in January 2021.